Cullinan Therapeutics Inc
CGEM10.370USD
+0.110+1.07%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
612.62MMarket Cap
LossP/E TTM
More Details of Cullinan Therapeutics Inc Company
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
Cullinan Therapeutics Inc Info
Ticker SymbolCGEM
Company nameCullinan Therapeutics Inc
IPO dateJan 08, 2021
CEOAhmed (Nadim)
Number of employees111
Security typeOrdinary Share
Fiscal year-endJan 08
AddressOne Main Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16174104650
Websitehttps://cullinantherapeutics.com/
Ticker SymbolCGEM
IPO dateJan 08, 2021
CEOAhmed (Nadim)
Company Executives of Cullinan Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Corinne Savill, Ph.D.
Ms. Corinne Savill, Ph.D.
Chief Business Officer
Chief Business Officer
240.99K
+18.43%
Dr. Jennifer Michaelson, Ph.D.
Dr. Jennifer Michaelson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
138.00K
-2.82%
Mr. Nadim Ahmed
Mr. Nadim Ahmed
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
68.03K
-64.17%
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. Mittie Doyle, M.D.
Dr. Mittie Doyle, M.D.
Director
Director
--
--
Dr. Andrew R. Allen, M.D., Ph.D.
Dr. Andrew R. Allen, M.D., Ph.D.
Director
Director
--
--
Mr. David Meek
Mr. David Meek
Independent Director
Independent Director
--
--
Ms. Mary Kay Fenton
Ms. Mary Kay Fenton
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
--
-100.00%
Mr. Stephen W. Webster
Mr. Stephen W. Webster
Independent Director
Independent Director
--
--
Ms. Jacquelyn (Jackie) Sumer
Ms. Jacquelyn (Jackie) Sumer
Chief Legal and Compliance Officer, Company Secretary
Chief Legal and Compliance Officer, Company Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Corinne Savill, Ph.D.
Ms. Corinne Savill, Ph.D.
Chief Business Officer
Chief Business Officer
240.99K
+18.43%
Dr. Jennifer Michaelson, Ph.D.
Dr. Jennifer Michaelson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
138.00K
-2.82%
Mr. Nadim Ahmed
Mr. Nadim Ahmed
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
68.03K
-64.17%
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. Mittie Doyle, M.D.
Dr. Mittie Doyle, M.D.
Director
Director
--
--
Dr. Andrew R. Allen, M.D., Ph.D.
Dr. Andrew R. Allen, M.D., Ph.D.
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lynx1 Capital Advisors LLC
15.17%
MPM BioImpact LLC
12.95%
BVF Partners L.P.
9.73%
BlackRock Institutional Trust Company, N.A.
6.23%
The Vanguard Group, Inc.
4.97%
Other
50.94%
Shareholders
Shareholders
Proportion
Lynx1 Capital Advisors LLC
15.17%
MPM BioImpact LLC
12.95%
BVF Partners L.P.
9.73%
BlackRock Institutional Trust Company, N.A.
6.23%
The Vanguard Group, Inc.
4.97%
Other
50.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.33%
Investment Advisor/Hedge Fund
29.58%
Hedge Fund
28.72%
Private Equity
3.28%
Research Firm
3.13%
Venture Capital
2.62%
Individual Investor
1.55%
Bank and Trust
0.20%
Pension Fund
0.08%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
319
64.92M
132.11%
+3.21M
2025Q3
325
61.69M
130.11%
-1.87M
2025Q2
320
66.57M
137.49%
-2.02M
2025Q1
325
68.79M
136.24%
-10.93M
2024Q4
313
69.80M
129.09%
+695.39K
2024Q3
302
68.91M
123.19%
+1.86M
2024Q2
290
67.03M
84.28%
+21.63M
2024Q1
267
43.43M
114.51%
-5.88M
2023Q4
259
40.67M
106.23%
+2.27M
2023Q3
252
38.37M
104.37%
+843.67K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lynx1 Capital Advisors LLC
4.40M
7.45%
+1.19M
+36.85%
Jun 30, 2025
MPM BioImpact LLC
7.65M
12.95%
--
--
Jun 30, 2025
BVF Partners L.P.
5.75M
9.73%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.70M
6.26%
-109.92K
-2.89%
Jun 30, 2025
The Vanguard Group, Inc.
3.01M
5.1%
-19.63K
-0.65%
Jun 30, 2025
Deerfield Management Company, L.P.
3.86M
6.53%
-5.29K
-0.14%
Jun 30, 2025
Blue Owl Capital Holdings LP
2.39M
4.04%
-50.00K
-2.05%
Jun 30, 2025
Kynam Capital Management LP
2.10M
3.55%
-242.63K
-10.37%
Jun 30, 2025
Citadel Advisors LLC
3.01M
5.09%
+395.43K
+15.13%
Jul 30, 2025
OrbiMed Advisors, LLC
1.92M
3.26%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.66%
Tema Oncology ETF
0.47%
State Street SPDR S&P Biotech ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
iShares Micro-Cap ETF
0.08%
Avantis US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.05%
Direxion Daily S&P Biotech Bull 3X Shares
0.05%
iShares Russell 2000 Value ETF
0.04%
iShares Biotechnology ETF
0.03%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.66%
Tema Oncology ETF
Proportion0.47%
State Street SPDR S&P Biotech ETF
Proportion0.09%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
iShares Micro-Cap ETF
Proportion0.08%
Avantis US Small Cap Equity ETF
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.05%
iShares Russell 2000 Value ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Cullinan Therapeutics Inc?
The top five shareholders of Cullinan Therapeutics Inc are:
Lynx1 Capital Advisors LLC holds 4.40M shares, accounting for 7.45% of the total shares.
MPM BioImpact LLC holds 7.65M shares, accounting for 12.95% of the total shares.
BVF Partners L.P. holds 5.75M shares, accounting for 9.73% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.70M shares, accounting for 6.26% of the total shares.
The Vanguard Group, Inc. holds 3.01M shares, accounting for 5.10% of the total shares.
Lynx1 Capital Advisors LLC holds 4.40M shares, accounting for 7.45% of the total shares.
MPM BioImpact LLC holds 7.65M shares, accounting for 12.95% of the total shares.
BVF Partners L.P. holds 5.75M shares, accounting for 9.73% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.70M shares, accounting for 6.26% of the total shares.
The Vanguard Group, Inc. holds 3.01M shares, accounting for 5.10% of the total shares.
What are the top three shareholder types of Cullinan Therapeutics Inc?
The top three shareholder types of Cullinan Therapeutics Inc are:
Lynx1 Capital Advisors LLC
MPM BioImpact LLC
BVF Partners L.P.
Lynx1 Capital Advisors LLC
MPM BioImpact LLC
BVF Partners L.P.
How many institutions hold shares of Cullinan Therapeutics Inc (CGEM)?
As of 2025Q4, 319 institutions hold shares of Cullinan Therapeutics Inc, with a combined market value of approximately 64.92M, accounting for 132.11% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 2.00%.
What is the biggest source of revenue for Cullinan Therapeutics Inc?
In --, the -- business generated the highest revenue for Cullinan Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
